Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Daiichi Sankyo
Cantor Fitzgerald
Julphar
QuintilesIMS
Chubb
Fish and Richardson
AstraZeneca

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,263,054

« Back to Dashboard

Which drugs does patent 8,263,054 protect, and when does it expire?

Patent 8,263,054 protects LATISSE and is included in one NDA.

This patent has fifteen patent family members in six countries.
Summary for Patent: 8,263,054
Title:Method of enhancing hair growth
Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I ##STR00001## wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R.sub.1 and R.sub.2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Inventor(s): Woodward; David F. (Lake Forest, CA), Vandenburgh; Amanda M (Huntington Beach, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/356,284
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,263,054
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,263,054

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,263,054

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,926,953 Method of enhancing hair growth ➤ Try a Free Trial
8,101,161 Method of enhancing hair growth ➤ Try a Free Trial
7,351,404 Method of enhancing hair growth ➤ Try a Free Trial
8,758,733 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,263,054

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003207843 ➤ Try a Free Trial
Australia 2008203212 ➤ Try a Free Trial
Australia 2010227111 ➤ Try a Free Trial
Australia 2012261499 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
McKesson
Cipla
Fuji
UBS
QuintilesIMS
McKinsey
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.